Post job

Competitor Summary. See how Facet Biotech compares to its main competitors:

  • Coherus BioSciences has the most employees (232).
  • The oldest company is Idera Pharmaceuticals, founded in 1989.
Work at Facet Biotech?
Share your experience

Facet Biotech vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
2008
4.2
Redwood City, CA1-75
2006
3.8
Emeryville, CA1$500,00050
1993
4.3
Morgan Hill, CA1$9.0M50
2005
3.8
Alameda, CA1$1.3M29
2007
3.7
Cambridge, MA1$37.4M124
1989
3.6
Cambridge, MA1$4.9M36
Histogen
2005
4.0
San Diego, CA1$17.8M19
2010
3.7
Redwood City, CA2$267.0M232

Rate Facet Biotech's competitiveness in the market.

Zippia waving zebra

Facet Biotech salaries vs competitors

Compare Facet Biotech salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Facet Biotech
$46,458$22.34-

Compare Facet Biotech job title salaries vs competitors

CompanyHighest salaryHourly salary
Facet Biotech
$32,509$15.63
Idera Pharmaceuticals
$41,094$19.76
Histogen
$35,172$16.91
Eureka Therapeutics
$34,743$16.70
Cerexa Inc.
$32,708$15.73
Epizyme
$32,566$15.66
Coherus BioSciences
$32,131$15.45
Aragen Bioscience
$32,024$15.40

Do you work at Facet Biotech?

Does Facet Biotech effectively differentiate itself from competitors?

Facet Biotech jobs

0

Facet Biotech and similar companies CEOs

CEOBio
Dennis M. Lanfear
Coherus BioSciences

Mr. Dennis M. Lanfear is a President and Chief Executive Officer at COHERUS BIOSCIENCES, INC. and is based in United States.

Steven J. Mento
Histogen

Grant C. Bogle
Epizyme

Vincent J. Milano
Idera Pharmaceuticals

Vincent Milano joined Idera as Chief Executive Officer in December 2014. Mr. Milano most recently served as Chairman, President, and Chief Executive Officer of ViroPharma, which was acquired by Shire Pharmaceuticals in January 2014. Under his stewardship, ViroPharma became a leading developer of innovative therapies for rare diseases, with the approval and commercialization of its lead product, Cinryze, for the treatment of hereditary angioedema in the United States and Europe. Mr. Milano joined ViroPharma in 1996 and served as Vice President, Chief Financial Officer, and Treasurer from 1997 to 2006 before becoming Chief Executive Officer. He was instrumental in building the company, including leading efforts to raise nearly $900 million in capital, as well as acquisitions of Lev Pharmaceuticals and the drug Vancocin from Eli Lilly. In addition, he played critical roles in business development and investor relations activities for ViroPharma, and contributed significantly to establishing the strategic focus of the company. Prior to joining ViroPharma, he served as a senior manager at KPMG LLP, an independent registered public accounting firm.

Axel Schleyer
Aragen Bioscience

Biotechnology executive with more than sixteen years of experience in business development for mid-sized and large biotechnology/pharmaceutical and healthcare companies. Key member of the Boehringer Ingelheim CMB Senior Leadership Team that sets strategic direction, and major contributor to management as a whole. Designing and implementing strategic business plans for US/Asia B2B services in the area of Life Sciences/Pharma. Experienced in building and leading high performance Sales / Business Development and Key Account teams, identifying new business opportunities and closing large business transactions. Extensive network and relationships with existing clients and industry contacts, proven track record of selling large, integrated offerings and extensive consultative sales experience. Spearheading large business development initiatives. Deep understanding of the Biotech/Pharma market: products and services, players, technologies, and a rolodex of contacts in related markets. Negotiation of in-licensing, research, development, and strategic manufacturing agreements as well as co-development agreements. Specialties: - Building and leading high performance teams in Asia and US - Strategic business planning and implementation - Managing and overseeing overall project acquisition/BD process - Cross cultural (Europe, US, Asia) and global leadership experience - Large USD value transactions for strategic B2B service agreements - Industry analysis, business strategy development, business plans and execution - Strong scientific background in Chemistry, Biology and Pharma

Facet Biotech competitors FAQs

Search for jobs